MS Ventures is a strategic, corporate venture capital fund that invests in emerging biotechnology companies. The fund was started in 2009 with the mandate to invest in early-stage innovative technologies.​ ​ MS Ventures manages the investment of € 2.5 million that Merck Serono has provided as seed funding for Calypso Biotech SA. Investors